under-appreci phase asset
unmet need initi buy
rel under-recogn stori attract pediatr
orphan liver diseas product design address real unmet need
approv therapi although data lead product view
appreci share like next month gain visibl
among investor under-appreci asset particularli current
initi coverag buy pt larg investor
address real unmet need pediatr orphan liver diseas posit includ
likelihood success lead candid pfic sale potenti
potenti expand indic current estimate strong cash
 inexpens valuat ev
lead candid top-line data expect pfic rare
sever inherit liver diseas children approv drug
ibat inhibitor lower serum bile acid sba pruritu sever itch skin
associ progress famili intrahepat cholestasi pfic children current
approv therapi condit pt /eu/japan combin
primari endpoint chang pruritu fda approv sba respond rate
ema approv month
data show reduct sba wk stat sig correl
sba reduct improv pruritu notabl competitor shire ibat
inhibitor maralixibat compar data albeit limit patient differ
tx durat view shown consist dose-depend efficaci
tx-relat safeti issu diarrhea vs maralixibat treat pt experienc
manag team strong commerci experi project /eu
launch peak annual sale
eu assum pt treat peak annual sale
current estimate expand indic alagil syndrom biliari atresia
pt base pfic goofic japan use
annual discount rate risk associ includ phase failur
pfic competit distant profit
gener estim cash share per
share valu take account capit
rais share january/
februari
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
lead product pfic gener sale start
peak /eu sale
expand indic addit program
elobixibat current assum current
pt consist pfic
mileston payment goofic elobixibat sale
japan healthcar royalti partner
phase asset pediatr orphan liver diseas
progress famili intrahepat cholestasi pfic
current approv therapi thu phase
lead product success show clear clinic
benefit view commerci risk rel low
posit phase data see likelihood phase success
addit potenti expand indic
could offer upsid current project
inexpens current valuat ev view
risk/reward attract
phase success pfic regulatori approv
clinic success addit pediatr cholestat
approv pfic peg fair valu
initi trial pfic
top-line data
initi trial elobixibat nash nonalcohol
steatohepat
initi trial reformul
cholestyramin bam bile acid malabsorpt
initi trial addit indic
 alagil syndrom biliari atresia
phase failur pfic
delay clinical/regulatori timelin
pfic fail phase peg fair valu
base estim cash
page
pleas see import disclosur inform page report
current clinic program
initi coverag buy rate pt
clinical-stag biopharmaceut compani primari focu pediatr orphan liver
associ bile acid metabol posit thesi includ likelihood
phase success lead candid primari indic pfic base
posit phase data potenti expand indic offer upsid
current project strong cash balanc suffici
inexpens current valuat ev offer signific upsid potenti
phase data posit
lead candid set begin phase trial pfic
spring top-line data current approv therapi
pfic rare sever inherit liver diseas children ibat
ileal bile acid transport inhibitor design lower serum bile acid sba pruritu
sever itch skin associ progress famili intrahepat cholestasi
pfic children current approv therapi condit
patient /eu/japan combin phase trial children
two dose vs placebo primari endpoint chang pruritu fda
approv serum bile acid sba respond rate ema approv month
subgroup phase pfic patient treatment result
serum bile acid sba reduct week statist signific
correl sba reduct improv pruritu notabl
competitor shire ibat inhibitor maralixibat phase begun base
phase data albeit limit patient data differ treatment durat view
shown consist dose-depend efficaci treatment-rel
safeti issu diarrhea vs maralixibat treat patient experienc diarrhea
manag team strong commerci experi expect
commerci /eu start peak
annual sale reach /eu assum patient
treat peak annual sale respect
current assumpt expand indic alagil
opportun plan start phase expand indic
estim preval alagil syndrome/biliari atresia respect
pt base npv analysi /eu sale pfic
probability-adjust goofic sales-rel mileston chronic
constip japan healthcar royalti partner use annual discount
rate current valuat estim potenti label expans
risk associ includ limit phase failur
pfic competit distant profit gener drug industri risk
page
pleas see import disclosur inform page report
clinical-stag biopharmaceut compani
focus
develop commerci new bile acid modul headquart
boston massachusett albireo form spin-out transact astrazeneca
azn ln buy assign right portfolio ibat ileal bile acid
transport inhibitor pre-clin product albireo albireo merg
publicli trade compani biodel name albireo expect
full-tim employe current
shown chart two proprietari drug candid clinic develop
lead candid enter phase spring select ibat inhibitor
pediatr orphan liver diseas progress famili intrahepat cholestasi pfic
second pipelin product proprietari formul cholestyramin
develop bile acid malabsorpt phase begin first ibat
inhibitor approv world-wide goofic elobixibat japan chronic constip
posit receiv sales-rel mileston payment base japanes sale
ea pharma/healthcar royalti partner royalti monet agreement
upcom clinic catalyst includ initi phase trial lead
product pfic spring initi phase trial bam
initi phase trial addit indic alagil
syndrom biliari atresia
page
pleas see import disclosur inform page report
sourc compani report jefferi
background bile acid ileal bile acid transport ibat
bile acid import digest product made liver store
gallbladd act emulsifi promot absorpt lipid includ fat-
solubl vitamin flow bile liver play critic role dietari absorpt
integr metabol process depend enterohepat circul
flow liver small intestin back liver bile acid
reabsorb way passiv mechan upper intestin major bile acid
reclaim ileum distal portion small intestin ileal bile
ibat also known apic sodium-depend bile acid transport brush border
membran glycoprotein predominantli found distal ileum transport move
bile acid lumen insid small intestin across apic brush border
membran mediat secret bile acid portal circul blood
page
pleas see import disclosur inform page report
productdescriptionindicationstatusmarket rightspat expiri famili intrahepat cholestasi initi spring site countri top-line data interim analysi plan two dose vs placebo month primari endpoint chang pruriti fda serum bile acid sba respons rate ema nap natur cours prognosi pfic effect biliari divers natur histori studi on-going led group netherland data subgroup show mean sba reduct atresiaphas initi potenti syndrom phase initi potenti cholestat condit primari scleros cholang psc phase initi potenti formul cholestyraminebil acid malabsorpt initi prior data show numer greater mean reduct daili bowel movement vs placebopharmaceut formul compris cholestyramin patent pend chronic constipationapprov japan enter royalti monet agreement japan healthcar royalti partnersalbireo right europ ex-ea pharma territori ea pharma japan select asian marketcom patent japan/u plu extens method use patent crystal modif pend nonalcohol steatohepat initi use patent expiri pend bile acid modulatormoa undisclosednonalcohol steatohepat nash pre-clin note ibat ileal bile acid transport sbm spontan bowel movement sba serum bile acid pfic famili intrahepat cholestasi pbc primari biliari cirrhosi moa mechan ibat ileal bile acid transport inhibitor capsul daili albireocomposit matter com /eu method use specifi cholestat liver diseas patent /euorphan drug exclus year approv /eu orphan drug design pfic pbc eu grant access prioriti medicin prime program ema pfic elobixibat select ibat inhibitor
circul gi tract liver inhibit transport via ibat
inhibitor lead impair ileal bile acid reabsorpt liver result
increas bile acid proxim colon excret
chart bile acid circul pfic caus defect bile transport
sourc compani report jefferi
select target condit ibat inhibitor
cholestasi reduct stoppag bile flow liver small intestin
caus disord liver bile duct pancrea condit
umbrella cholestat pruritu excess itch reliev
scratch includ progress famili intrahepat cholestasi pfic alagil
syndrom biliari atresia current approv therapi condit
progress famili intrahepat cholestasi pfic autosom
recess cholestat disord hepatocyt liver cell less abl
secret bile result excess bile acid build-up liver failur thrive
cirrhosi need surgic intervent three type pfic
 repres
case exact preval unknown estim pfic occur
everi peopl world-wide translat estim
preval individu major pharmaceut market eu
alagil syndrom also known alagille-watson syndrom alg
autosom domin genet disord abnorm liver heart
skeleton eye kidney characterist facial appear broad
promin forehead deep-set eye small point chin one major
page
pleas see import disclosur inform page report
featur syndrom liver damag caus pauciti bile duct
carri bile liver gallbladd small intestin similar
pfic off-label drugs/surgeri remain best option afflict preval
alagil syndrom estim one newborn equat
patient eu japan
biliari atresia rare diseas liver bile duct occur infant
symptom develop week birth caus partial
total blockag bile duct prevent flow bile liver
small intestin lead cholestasi accumul bile liver
time lead cirrhosi loss liver tissu current standard treatment
kasai procedur involv surgic bypass block bile
duct prevent liver damag howev one four individu
undergo kasai procedur surviv twenti without need
liver transplant believ would best suit patient
undergon kasai procedur estim potenti patient
 /eu/japan would elig
chart select condit pediatr cholestat pruritu
sourc compani report jefferi
page
pleas see import disclosur inform page report
diseasepficalagil syndromebiliari atresia pediatr cholestat pruritusdescriptiongenet disord caus defect bile acid transport besp result accumul bile acid liver ultim liver failuregenet disord abnorm variou organ liver damag caus pauciti bile duct prevent bile flow liver small intestinestructur partial total blockag bile duct prevent bile flow liver small instestinecannot reliabl reliev newborns- preval eu bile salt export pump protein presentationno approv therapi current
new minim absorb daili oral administ ibat
inhibitor enter phase spring work divert bile acid
would normal recircul small intestin liver thu reduc bile
acid level serum liver minim system exposur show
favor toler profil phase
composit matter com patent expir septemb
 /eu two method use patent expir novemb eu
grant orphan drug design pfic eu year
market exclus eu respect upon approv per ema
ad prioriti medicin prime program pfic
background pfic
progress famili intrahepat cholestasi pfic rare inherit condit autosom
recess disord requir two copi abnorm gene mother father
diseas manifest children unabl secret bile liver
even though larg bile duct open cholestasi patient pfic usual present
earli childhood cholestasi jaundic failur thrive intens pruritu
characterist begin infanc averag age onset month jaundic
sever itching/pruritu progress cirrhosi within first decad life although
may progress slowli well adolesc condit typic fatal age
without surgeri liver transplant
shown chart base specif gene defect three type pfic pfic
discov year ago clayton rj et al journal pediatr amish
descend joseph byler thu name byler diseas condit
discov non-amish individu term byler syndrom coin
condit affect male femal equal account
pfic involv defect bile acid secret wherea involv defect
exact preval pfic unknown estim patient
 /eu/japan base need transplant birth rate includ
 /eu incid estim one everi birth
current approv drug pfic off-label drug use symptomat
relief includ ursodeoxychol acid antihistamin rifampin bile acid-
bypass partial extern biliari drainag pebd gallbladd extern
ileostomi bag pebd surgeri provid strong clinic rational ibat
inhibit studi children pfic alagil syndrom reduct serum bile
acid sba observ post-pebd baselin level mol/l mol/l
year post-pebd mol/l year post-pebd yang et al journal
pediatr gastroenterolog nutrit addit patient supplement
fat-solubl vitamin occasion medium-chain triglycerid improv growth
note would benefit patient yet surgeri liver
transplant estim pfic patient current /eu
respect approxim estim total pfic patient popul current
page
pleas see import disclosur inform page report
chart three type famili intrahepat cholestasi pfic
sourc compani report jefferi
clinic program pfic
plan initi phase trial patient spring
phase trial year old major enrol
patient year old per group random double-blind placebo-
control studi demonstr efficaci safeti two dose g/kg vs
g/kg vs placebo children exclud patient
bsep bile salt export pump function per conduct
clinic site countri treatment durat six month
primari endpoint chang pruritu fda approv serum bile acid sba
respond rate ema approv sba respons rate eu approv
page
pleas see import disclosur inform page report
total protein mediat aminophospholipidtransloc plasma membran bile salt export pump multi-drug resist protein bile acid secretionimpair bile acid secretionreduc biliari phospholipid secretionjaundic sever pruritu first month life episod symptomsfirst month life sever vs continu cours symptomson third present cholestasi infanc pruritu less sever vs progress biliari cirrhosi liver failur rapidbil acid level markedli elev usual mmol/l vs normal concentr mmol/l markedli elev usual mmol/l vs normal concentr mmol/l markedli elev usual mmol/l vs normal concentr mmol/l sign symptomsshort statur deaf diarrhea pancreat low fat-solubl vitamin serum level typic develop liver failur adulthoodtyp relat liver diseas often develop liver failur within first year life cancer develop diagnosisrel liver diseas usual appear later infanc earli childhood slow progress liver failur occur childhood adulthoodhepatocellular carcinoma risknorisk first yearnoggt level diagnosi injuri bile duct normal u/l lownorm u/l low elev bile acid level male mol/l mol/l femal ggt -glutamyl transferas birth patient /eu/japan per pfic affect race rarer found western european white north african arab popul
respons base either reduct reduct least specifi level
within rang mol/l
subgroup phase pfic patient treatment result
serum bile acid reduct week phase trial uniqu
retreat low/high dose includ patient pediatr cholestat liver
diseas pfic subtyp includ alagil syndrom
biliari atresia intrahepat cholestasi patient administ
oral qd four week studi five differ dose evalu
 g/kg mean baselin serum bile acid level mol/l uln
demonstr reduct serum bile acid level across five dose cohort
substanti serum bile acid reduct averag pfic patient
exclud one bsep function low sba baselin note
two exclud patient non-phas qualifi patient per
mild transient assess relat treatment sae design
treatment-rel importantli rate diarrhea studi vs
treatment-rel diarrhea shire maralixibat addit statist
signific correl reduct serum bile acid improv
pruritu vas-itch whitington-itch po-scorad-itch
po-scorad-sleep studi present oral late breaker session
european associ studi liver easl receiv presidenti
poster distinct american associ studi liver diseas aasld
chart phase data pediatr cholestat liver diseas
sourc compani report jefferi
phase trial well toler dose-rel
reduct serum bile acid observ three part phase
dose mad phase three differ dose qd qd bid
seven day mad phase evalu combin bile acid
sequestr seven day gener well toler dose group
treatment-rel seriou advers event addit treatment
associ dose-rel reduct serum bile acid increas level bile acid
intermedi decreas level fibroblast
growth factor mrna absent normal liver overexpress
respons extrahepat intrahepat cholestasi level
consist ibat inhibit level
mous model certain gene induc cholestat liver injuri
administr reduc bile acid serum level well liver enzym alanin
aminotransferas alt alkalin phosphatas alp
page
pleas see import disclosur inform page report
baselin sba level chang baselin serun bile acid includ pfic patient bile salt export pump bsep function non-phas qualifi patient includ pfic patient low baselin sba non-phas qualifi patient
competit landscap pfic
current approv therapi progress famili intrahepat cholestasi
shown chart two ibat inhibitor activ clinic develop
includ maralixibat
shire shp ln buy start phase trial
maralixibat pfic primari complet date june per
clinicaltri gov random double-blind placebo-control trial
year old enrol pfic patient total sba uln weekli itchro ob
score baselin primari endpoint treatment respons measur
observ itch report outcom itchro ob week maralixibat oral solut
daili vs placebo secondari endpoint includ reduct sba
baselin disappear prutitu among other primari cohort includ patient
two document mutant allel without bile salt export
pump bsep function biallel truncat mutat exploratori cohort
includ patient biallel truncat mutat infant
birth month age pfic pfic intern extern
pebd biliari divers surgeri unsatisfactori pruritu control biliari
divers revers
phase open-label studi data maralixibat children pfic indigo
show reduct sba baselin
week reduct mol/l mol/l baselin week itch
report outcom itchro reduct score reduct
baselin week efficaci data avail patient
reach week patient sba level
normal mol/l reduc pruritu
improv point transaminas and/or bilirubin normal
maralixibat treatment-emerg advers event teae occur
seriou teae one discontinu teae includ pyrexia diarrhea
cough abdomin pain vomit
healthi volunt studi appear dose-respons
 per day sba reduct
page
pleas see import disclosur inform page report
